Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
TP53 mutation
Cancer:
Neuroendocrine Tumor
Drug:
pazopanib
(
Multi-tyrosine kinase inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Oncotarget
Title:
Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
Excerpt:
...Three GEP-NET patients with TP53 mutations demonstrated a durable response to pazopanib, either as PR or achievement of stable disease (Figure 2)…
DOI:
10.18632/oncotarget.6602
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login